G. Roche, B. Squibb, M. , and N. ,

A. I. Romero, N. Chaput, C. Robert, L. I. Development-of-methodology:-a, V. Romero et al., Zitvogel Acquisition of data (provided animals, acquired and managed patients, provided facilities

H. A. Tawbi and J. M. Kirkwood, Management of metastatic melanoma, Semin Oncol, vol.34, pp.532-577, 2007.

M. L. Lee, K. Tomsu, V. Eschen, and K. B. , Duration of survival for disseminated malignant melanoma: results of a meta-analysis, Melanoma Res, vol.10, pp.81-92, 2000.

S. S. Agarwala, J. M. Kirkwood, M. Gore, B. Dreno, N. Thatcher et al., Temozolomide for the treatment of brain metastases associated with metastatic melanoma: a phase II study, J Clin Oncol, vol.22, pp.2101-2108, 2004.

M. R. Middleton, J. J. Grob, N. Aaronson, G. Fierlbeck, W. Tilgen et al., Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma, J Clin Oncol, vol.18, pp.158-66, 2000.

H. Davies, G. R. Bignell, C. Cox, P. Stephens, S. Edkins et al., Mutations of the BRAF gene in human cancer, Nature, vol.417, pp.949-54, 2002.

T. Eisen, T. Ahmad, K. T. Flaherty, M. Gore, S. Kaye et al., Sorafenib in advanced melanoma: a phase II randomised discontinuation trial analysis, Br J Cancer, vol.95, pp.581-587, 2006.

K. T. Flaherty, S. J. Lee, F. Zhao, L. M. Schuchter, L. Flaherty et al., Phase III trial of carboplatin and paclitaxel with or without sorafenib in metastatic melanoma, J Clin Oncol, vol.31, pp.373-382, 2013.

A. Hauschild, S. S. Agarwala, U. Trefzer, D. Hogg, C. Robert et al., Results of a phase III, randomized, placebo-controlled study of sorafenib in combination with carboplatin and paclitaxel as second-line treatment in patients with unresectable stage III or stage IV melanoma, J Clin Oncol, vol.27, pp.2823-2853, 2009.

R. K. Amaravadi, L. M. Schuchter, D. F. Mcdermott, A. Kramer, L. Giles et al., Phase II trial of temozolomide and sorafenib in advanced melanoma patients with or without brain metastases, Clin Cancer Res, vol.15, pp.7711-7719, 2009.

F. S. Hodi, S. J. O'day, D. F. Mcdermott, R. W. Weber, J. A. Sosman et al., Improved survival with ipilimumab in patients with metastatic melanoma, N Engl J Med, vol.363, pp.711-734, 2010.

C. Robert, L. Thomas, I. Bondarenko, S. O'day, J. Weber et al., Ipilimumab plus dacarbazine for previously untreated metastatic melanoma, N Engl J Med, vol.364, pp.2517-2543, 2011.

T. Boon and P. G. Coulie, Van den Eynde BJ, van der Bruggen P. Human T cell responses against melanoma, Annu Rev Immunol, vol.24, pp.175-208, 2006.

P. M. Arlen, J. L. Gulley, C. Parker, L. Skarupa, M. Pazdur et al., A randomized phase II study of concurrent docetaxel plus vaccine versus vaccine alone in metastatic androgen-independent prostate cancer, Clin Cancer Res, vol.12, pp.1260-1269, 2006.

J. Schlom, P. M. Arlen, and J. L. Gulley, Cancer vaccines: moving beyond current paradigms, Clin Cancer Res, vol.13, pp.3776-82, 2007.

L. Zitvogel, L. Apetoh, F. Ghiringhelli, F. Andre, A. Tesniere et al., The anticancer immune response: indispensable for therapeutic success?, J Clin Invest, vol.118, pp.1991-2001, 2008.

F. Ghiringhelli, L. Apetoh, A. Tesniere, L. Aymeric, Y. Ma et al., Activation of the NLRP3 inflammasome in dendritic cells induces IL-1beta-dependent adaptive immunity against tumors, Nat Med, vol.15, pp.1170-1178, 2009.
URL : https://hal.archives-ouvertes.fr/hal-00419823

R. Ramakrishnan, D. Assudani, S. Nagaraj, T. Hunter, H. I. Cho et al., Chemotherapy enhances tumor cell susceptibility to CTL-mediated killing during cancer immunotherapy in mice, J Clin Invest, vol.120, pp.1111-1135, 2010.

S. Ladoire, L. Arnould, L. Apetoh, B. Coudert, F. Martin et al., Pathologic complete response to neoadjuvant chemotherapy of breast carcinoma is associated with the disappearance of tumor-infiltrating foxp3 þ regulatory T cells, Clin Cancer Res, vol.14, pp.2413-2433, 2008.

J. Vincent, G. Mignot, F. Chalmin, S. Ladoire, M. Bruchard et al., 5-Fluorouracil selectively kills tumor-associated myeloid-derived suppressor cells resulting in enhanced T cell-dependent antitumor immunity, Cancer Res, vol.70, pp.3052-61, 2010.

M. Chapon, C. Randriamampita, E. Maubec, C. Badoual, S. Fouquet et al., Progressive upregulation of PD-1 in primary and metastatic melanomas associated with blunted TCR signaling in infiltrating T lymphocytes, J Invest Dermatol, vol.131, pp.1300-1307, 2011.

C. M. Koebel, W. Vermi, J. B. Swann, N. Zerafa, S. J. Rodig et al., Adaptive immunity maintains occult cancer in an equilibrium state, Nature, vol.450, pp.903-910, 2007.

L. Zitvogel, J. I. Mayordomo, T. Tjandrawan, A. B. Deleo, M. R. Clarke et al., Therapy of murine tumors with tumor peptide-pulsed dendritic cells: dependence on T cells, B7 costimulation, and T helper cell 1-associated cytokines, J Exp Med, vol.183, pp.87-97, 1996.

C. S. Vetter, W. Lieb, E. B. Brocker, and J. C. Becker, Loss of nonclassical MHC molecules MIC-A/B expression during progression of uveal melanoma, Br J Cancer, vol.91, pp.1495-1504, 2004.

A. Diefenbach, E. R. Jensen, A. M. Jamieson, and D. H. Raulet, Rae1 and H60 ligands of the NKG2D receptor stimulate tumour immunity, Nature, vol.413, pp.165-71, 2001.

M. J. Smyth, J. Swann, E. Cretney, N. Zerafa, W. M. Yokoyama et al., NKG2D function protects the host from tumor initiation, J Exp Med, vol.202, pp.583-591, 2005.

W. H. Kruit, H. H. Van-ojik, V. G. Brichard, B. Escudier, T. Dorval et al., Phase 1/2 study of subcutaneous and intradermal immunization with a recombinant MAGE-3 protein in patients with detectable metastatic melanoma, Int J Cancer, vol.117, pp.596-604, 2005.

D. Valmori, N. E. Souleimanian, V. Tosello, N. Bhardwaj, S. Adams et al., Vaccination with NY-ESO-1 protein and CpG in Montanide induces integrated antibody/Th1 responses and CD8 T cells through cross-priming, Proc Natl Acad Sci U S A, vol.104, pp.8947-52, 2007.

K. J. Livak and T. D. Schmittgen, Analysis of relative gene expression data using real-time quantitative PCR and the 2(Àdelta delta C(T)) method, Methods, vol.25, pp.402-410, 2001.

J. Desfrancois, L. Derre, M. Corvaisier, L. Mevel, B. Catros et al., Increased frequency of nonconventional double positive CD4CD8 alphabeta T cells in human breast pleural effusions, Int J Cancer, vol.125, pp.374-80, 2009.

A. E. Fasth, N. K. Bjorkstrom, M. Anthoni, K. J. Malmberg, and V. Malmstrom, Activating NK-cell receptors co-stimulate CD4(þ)CD28(À) T cells in patients with rheumatoid arthritis, Eur J Immunol, vol.40, pp.378-87, 2010.

B. Meresse, Z. Chen, C. Ciszewski, M. Tretiakova, G. Bhagat et al., Coordinated induction by IL15 of a TCR-independent NKG2D signaling pathway converts CTL into lymphokine-activated killer cells in celiac disease, Immunity, vol.21, pp.357-66, 2004.

F. Stehle, K. Schulz, C. Fahldieck, J. Kalich, R. Lichtenfels et al., Reduced immunosuppressive properties of axitinib in comparison with other tyrosine kinase inhibitors, J Biol Chem, vol.288, pp.16334-16381, 2013.

C. Maccalli, D. Nonaka, A. Piris, D. Pende, L. Rivoltini et al., NKG2D-mediated antitumor activity by tumor-infiltrating lymphocytes and antigen-specific T-cell clones isolated from melanoma patients, Clin Cancer Res, vol.13, pp.7459-68, 2007.

V. Groh, K. Smythe, Z. Dai, and T. Spies, Fas-ligand-mediated paracrine T cell regulation by the receptor NKG2D in tumor immunity, Nat Immunol, vol.7, pp.755-62, 2006.

V. Groh, J. Wu, C. Yee, and T. Spies, Tumour-derived soluble MIC ligands impair expression of NKG2D and T-cell activation, Nature, vol.419, pp.734-742, 2002.

Z. Dai, C. J. Turtle, G. C. Booth, S. R. Riddell, T. A. Gooley et al., Normally occurring NKG2D þ CD4 þ T cells are immunosuppressive and inversely correlated with disease activity in juvenile-onset lupus, J Exp Med, vol.206, pp.793-805, 2009.

D. Capraru, A. Muller, E. Csernok, W. L. Gross, K. Holl-ulrich et al., Expansion of circulating NKG2Dþ effector memory T-cells and expression of NKG2D-ligand MIC in granulomaous lesions in Wegener's granulomatosis, Clin Immunol, vol.127, pp.144-50, 2008.

A. Komocsi, P. Lamprecht, E. Csernok, A. Mueller, K. Holl-ulrich et al., Peripheral blood and granuloma CD4(þ)CD28(À) T cells are a major source of interferon-gamma and tumor necrosis factor-alpha in Wegener's granulomatosis, Am J Pathol, vol.160, pp.1717-1741, 2002.

V. Groh, A. Bruhl, H. El-gabalawy, J. L. Nelson, and T. Spies, Stimulation of T cell autoreactivity by anomalous expression of NKG2D and its MIC ligands in rheumatoid arthritis, Proc Natl Acad Sci U S A, vol.100, pp.9452-9459, 2003.

M. Allez, V. Tieng, A. Nakazawa, X. Treton, V. Pacault et al., CD4 þ NKG2D þ T cells in Crohn's disease mediate inflammatory and cytotoxic responses through MICA interactions, Gastroenterology, vol.132, pp.2346-58, 2007.

A. I. Roberts, L. Lee, E. Schwarz, V. Groh, T. Spies et al., NKG2D receptors induced by IL-15 costimulate CD28-negative effector CTL in the tissue microenvironment, J Immunol, vol.167, pp.5527-5557, 2001.

J. Desfrancois, A. Moreau-aubry, V. Vignard, Y. Godet, A. Khammari et al., Double positive CD4CD8 alphabeta T cells: a new tumor-reactive population in human melanomas, PLoS ONE, vol.5, p.8437, 2010.

N. N. Hunder, H. Wallen, J. Cao, D. W. Hendricks, J. Z. Reilly et al., Treatment of metastatic melanoma with autologous CD4 þ T cells against NY-ESO-1, N Engl J Med, vol.358, pp.2698-703, 2008.

S. K. Biswas and A. Mantovani, Macrophage plasticity and interaction with lymphocyte subsets: cancer as a paradigm, Nat Immunol, vol.11, pp.889-96, 2010.

Y. Xie, A. Akpinarli, C. Maris, E. L. Hipkiss, M. Lane et al., Naive tumor-specific CD4(þ) T cells differentiated in vivo eradicate established melanoma, J Exp Med, vol.207, pp.651-67, 2010.

T. Ohteki, K. Suzue, C. Maki, T. Ota, and S. Koyasu, Critical role of IL-15-IL-15R for antigen-presenting cell functions in the innate immune response, Nat Immunol, vol.2, pp.1138-1181, 2001.

M. C. Ochoa, G. Mazzolini, S. Hervas-stubbs, M. F. De-sanmamed, P. Berraondo et al., Interleukin-15 in gene therapy of cancer, Curr Gene Ther, vol.13, pp.15-30, 2013.